In prostate cancer, the initial biopsy carries more information than we thought @adam-sowalsky.bsky.social & team discover aggressive untreated prostate cancers harbor a tumor cell subpopulation with elevated HER2 levels that may be sensitive to inhibitors: www.jci.org/articles/vie...

I'm pleased to share the latest paper from my lab, published online today at @jclinical-invest.bsky.social www.jci.org/articles/vie.... Patients with high risk prostate cancers that resist intense androgen derivation therapy harbor cancer cells that are sensitive to HER2 inhibitors. A "skytorial."

🚨New publication alert🚨 Typeset version of our most recent publication in European Urology just hit! Wonderful collaboration with @mishabeltran.bsky.social @adam-sowalsky.bsky.social and Pete Nelson at @fredhutch.bsky.social! 👇

When I was on paternity leave with my son (who is now 6-1/2) my good friend and long-time collaborator Huihui Ye called and asked me to help with genomic profiling of a rare variant of kidney cancer. That paper was published today in @modernpathology.bsky.social. authors.elsevier.com/c/1l3Ih3B8d9...

Great mid-week news on the publication front! Could it be that our GPC3-selective radiotheranostics agents aimed at #HCC could be repurposed for neuroendocrine prostate cancer? Fun collaboration with Dr. Adam Sowalsky, Himisha Beltran and Peter Nelson! Stay tuned! #radiopharmaceuticals #pcsm

Happy to finally have this work out. Enza-resistance in PCa via upregulation of ARv7 and increased chromatin accessibility. Congrats to lead author (and newly minted PCF YI) Larysa Poluben! She put a tremendous amount of work into this and deserves all the 👏👏👏. pubmed.ncbi.nlm.nih.gov/39709604/